Profound Medical Operating Income Over Time
| PROF Stock | USD 6.49 0.17 2.69% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Profound Medical Performance and Profound Medical Correlation. Can Health Care Equipment & Supplies industry sustain growth momentum? Does Profound have expansion opportunities? Factors like these will boost the valuation of Profound Medical. Anticipated expansion of Profound directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Profound Medical demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (1.32) | Revenue Per Share | Quarterly Revenue Growth 0.868 | Return On Assets | Return On Equity |
Investors evaluate Profound Medical Corp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Profound Medical's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Profound Medical's market price to deviate significantly from intrinsic value.
It's important to distinguish between Profound Medical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Profound Medical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Profound Medical's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Operating Income Analysis
Compare Profound Medical Corp and related stocks such as TriSalus Life Sciences, MaxCyte, and Perspective Therapeutics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TLSI | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (36.4 M) | (54.5 M) | (36.2 M) | (32.5 M) | (34.2 M) |
| MXCT | (2 M) | (2 M) | (2 M) | (804.7 K) | (1.3 M) | (761.1 K) | (2.7 M) | (9.3 M) | (8.4 M) | (12.4 M) | (11.1 M) | (18.2 M) | (27.4 M) | (48.3 M) | (51.2 M) | (46.1 M) | (43.8 M) |
| CATX | (1.2 M) | (3 M) | (3.6 M) | (4.1 M) | (4.6 M) | (4.3 M) | (5.1 M) | (6.3 M) | (5.3 M) | (3.5 M) | (3.4 M) | (7.4 M) | (15.2 M) | (40.9 M) | 10.5 M | 9.4 M | 9.9 M |
| LNSR | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (12.7 M) | (18.5 M) | (19.7 M) | (20.2 M) | (12.2 M) | (10.7 M) | (9.6 M) | (10.1 M) |
| AVR | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (16.9 M) | (31.1 M) | (48.1 M) | (78.4 M) | (70.5 M) | (67 M) |
| NNOX | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (22.6 M) | (43.9 M) | (61.6 M) | (109.7 M) | (62.6 M) | (56.7 M) | (51.1 M) | (53.6 M) |
| PRE | 101.2 M | 1.4 B | 1.4 B | 833.2 M | 1.3 B | 642.1 M | (20.8 M) | (20.8 M) | (20.8 M) | (20.8 M) | (995.1 K) | (56.7 M) | (66 M) | (51.9 M) | (48.1 M) | (43.3 M) | (41.2 M) |
| STIM | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (13.6 M) | (19.8 M) | (26.9 M) | (22.3 M) | (27.6 M) | (35.1 M) | (30.6 M) | (34.6 M) | (31.1 M) | (32.7 M) |
| OWLT | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (7 M) | (55.8 M) | (84.6 M) | (28.6 M) | (20.2 M) | (18.2 M) | (19.1 M) |
| ARMP | (5.4 M) | (3.9 M) | (4 M) | (15 M) | (14.1 M) | (10.2 M) | (23.4 M) | (16.2 M) | (12.5 M) | (19.1 M) | (21.6 M) | (23.8 M) | (36.9 M) | (40.9 M) | (42.4 M) | (38.2 M) | (36.3 M) |
Profound Medical Corp and related stocks such as TriSalus Life Sciences, MaxCyte, and Perspective Therapeutics Operating Income description
Operating Income is the amount of profit realized from Profound Medical Corp operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Profound Medical Corp is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Profound Medical Corp | PROF |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 2400 Skymark Avenue, |
| Exchange | NASDAQ Exchange |
USD 6.49
Check out Profound Medical Performance and Profound Medical Correlation. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Profound Medical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.